MX2011007451A - Composiciones farmaceuticas que comprenden derivados de 2-oxo-1 pirrolidina. - Google Patents

Composiciones farmaceuticas que comprenden derivados de 2-oxo-1 pirrolidina.

Info

Publication number
MX2011007451A
MX2011007451A MX2011007451A MX2011007451A MX2011007451A MX 2011007451 A MX2011007451 A MX 2011007451A MX 2011007451 A MX2011007451 A MX 2011007451A MX 2011007451 A MX2011007451 A MX 2011007451A MX 2011007451 A MX2011007451 A MX 2011007451A
Authority
MX
Mexico
Prior art keywords
oxo
pharmaceutical compositions
pyrrolidine derivatives
pyrrolidine
derivatives
Prior art date
Application number
MX2011007451A
Other languages
English (en)
Inventor
Domenico Fanara
Monique Berwaer
Serge Cuypers
Valery Barillaro
Martine Larbanoix
Frederic Dargelas
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Publication of MX2011007451A publication Critical patent/MX2011007451A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se relaciona con una formulación de liberación inmediata de compuestos farmacéuticos.
MX2011007451A 2009-01-29 2010-01-27 Composiciones farmaceuticas que comprenden derivados de 2-oxo-1 pirrolidina. MX2011007451A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09100084 2009-01-29
PCT/EP2010/050893 WO2010086315A1 (en) 2009-01-29 2010-01-27 Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives

Publications (1)

Publication Number Publication Date
MX2011007451A true MX2011007451A (es) 2011-08-03

Family

ID=40668146

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011007451A MX2011007451A (es) 2009-01-29 2010-01-27 Composiciones farmaceuticas que comprenden derivados de 2-oxo-1 pirrolidina.

Country Status (16)

Country Link
US (1) US20110275693A1 (es)
EP (1) EP2391351B1 (es)
JP (1) JP5599115B2 (es)
KR (1) KR101665001B1 (es)
CN (2) CN104906085A (es)
AU (1) AU2010209790B2 (es)
BR (1) BRPI1007211A2 (es)
CA (1) CA2747396C (es)
DK (1) DK2391351T3 (es)
EA (1) EA022080B1 (es)
ES (1) ES2520990T3 (es)
HK (1) HK1209649A1 (es)
IL (1) IL213546A0 (es)
MX (1) MX2011007451A (es)
PL (1) PL2391351T3 (es)
WO (1) WO2010086315A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2346500B1 (en) 2008-10-16 2017-05-17 The Johns Hopkins University Methods and compositions for improving cognitive function
KR101640164B1 (ko) * 2009-01-29 2016-07-15 유씨비 파마, 에스.에이. ２­옥소­１­피롤리딘 유도체를 포함하는 약학적 조성물
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
CA2904767C (en) 2013-03-15 2022-06-21 Agenebio, Inc. Methods and compositions for improving cognitive function
US10806717B2 (en) 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function
CN104800176A (zh) * 2015-04-23 2015-07-29 广东赛烽医药科技有限公司 一种布瓦西坦口崩片及其制备方法
EA034167B8 (ru) 2015-05-22 2021-04-27 Эйджинбайо, Инк. Фармацевтические композиции леветирацетама пролонгированного высвобождения
CN106902358B (zh) 2015-12-21 2020-07-10 广州市香雪制药股份有限公司 口服制剂及其制备方法
EP3397253A1 (en) 2015-12-30 2018-11-07 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of seizure-related disorders
CN111374956A (zh) * 2018-12-28 2020-07-07 上海迪赛诺生物医药有限公司 改进的布瓦西坦速释制剂
EP4431086A1 (en) 2023-03-16 2024-09-18 Adalvo Limited Pharmaceutical composition comprising (2s)-2-[(4r)-2-oxo-4-propyltetrahydro-1h-pyrrol-1-yl]butanamide
EP4491177A1 (en) 2023-07-14 2025-01-15 Sanovel Ilac Sanayi ve Ticaret A.S. Film coated tablets of brivaracetam
EP4491176A1 (en) 2023-07-14 2025-01-15 Sanovel Ilac Sanayi ve Ticaret A.S. A film coated tablet comprising brivaracetam
EP4527378A1 (en) 2023-09-22 2025-03-26 Sanovel Ilac Sanayi ve Ticaret A.S. A film coated tablet of brivaracetam

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595761A (en) * 1994-01-27 1997-01-21 The Board Of Regents Of The University Of Oklahoma Particulate support matrix for making a rapidly dissolving tablet
AP2003002900A0 (en) * 2001-05-01 2003-12-31 Pfizer Prod Inc Method for manufacturing a low dose pharmaceutical composition
JP2005298338A (ja) * 2002-02-27 2005-10-27 Eisai Co Ltd 速崩壊性圧縮成形製剤
EP1731149A1 (en) * 2005-06-08 2006-12-13 Ucb S.A. Use of 2-oxo-1-pyrrolidone derivatives for the treatment of diseases characterized by progressive myoclonic epilepsy
EP2041084B1 (en) * 2006-06-08 2013-11-06 UCB Pharma, S.A. Co-crystals of pyrrolidinones
KR101640164B1 (ko) * 2009-01-29 2016-07-15 유씨비 파마, 에스.에이. ２­옥소­１­피롤리딘 유도체를 포함하는 약학적 조성물

Also Published As

Publication number Publication date
CN104906085A (zh) 2015-09-16
BRPI1007211A2 (pt) 2019-09-24
JP5599115B2 (ja) 2014-10-01
CN102300562A (zh) 2011-12-28
ES2520990T3 (es) 2014-11-12
KR101665001B1 (ko) 2016-10-11
JP2012516303A (ja) 2012-07-19
EA201101118A1 (ru) 2012-03-30
AU2010209790A1 (en) 2011-08-18
IL213546A0 (en) 2011-07-31
PL2391351T3 (pl) 2015-02-27
CA2747396C (en) 2015-12-08
EA022080B1 (ru) 2015-10-30
WO2010086315A1 (en) 2010-08-05
CA2747396A1 (en) 2010-08-05
KR20120008023A (ko) 2012-01-25
US20110275693A1 (en) 2011-11-10
AU2010209790B2 (en) 2014-01-16
EP2391351B1 (en) 2014-08-20
HK1209649A1 (en) 2016-04-08
DK2391351T3 (da) 2014-12-01
EP2391351A1 (en) 2011-12-07

Similar Documents

Publication Publication Date Title
MX2011007267A (es) Composiciones farmaceuticas que comprenden derivados de 2-oxo-1-pirrolidina.
JOP20180102A1 (ar) مركب صيدلاني
EA201101118A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
MX2011008864A (es) Tetrahidroazolopirazinas sulfoniladas y su uso como productos medicinales.
PT2373681T (pt) Composições farmacêuticas de albiglutida
MX2011010311A (es) Formulaciones farmaceuticas que comprenden derivados de nitrocatecol y metodos para hacer las mismas.
MX2019012939A (es) Formulaciones que contienen linaclotida para administracion oral.
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
IN2012DN02793A (es)
IL219369A0 (en) Solid pharmaceutical compositions containing an integrase inhibitor
TN2009000510A1 (en) Extended release formulation of nevirapine
WO2010049449A3 (en) Novel salts of sunitinib
MX2010004604A (es) Derivados de pirazol como inhibidores de 5-lo.
WO2010006904A3 (en) Crystalline forms of rabeprazole sodium
ZA201102652B (en) Pharmaceutical composition utilising combinations of variants of the gonadotropin-liberating hormane (gnrh) as immunogen
MX339361B (es) Derivados de alternano.
IL210279A0 (en) Extended release compositions for high solubility, high permeability acdtive pharmaceutical ingredients
WO2011045774A3 (en) Extended release pharmaceutical compositions of paliperidone and processes of preparation thereof
EP2568810A4 (en) COMPOSITIONS OF DARUNAVIR
ZA201101053B (en) Pharmaceutical compositions of samatotrophic hormones
PT2429501T (pt) Composições de libertação imediata de fármaco
IN2013MU03317A (es)
PL2277511T3 (pl) Kompozycje farmaceutyczne lewetiracetamu o przedłużonym uwalnianiu
HK1178078A (en) Process for the preparation of pharmaceutical compositions for the sustained release of somatostatin analogs
HK1178078B (en) Process for the preparation of pharmaceutical compositions for the sustained release of somatostatin analogs

Legal Events

Date Code Title Description
FG Grant or registration